Projects and Grants


Cyclin A2 and Cardiac Repair

Understanding the mechanism of cyclin A2 mediated cardiac repair, whether it occurs by:

  1. Activation and differentiation of endogenous cardiac stem cells.
  2. Dedifferentiation of adult cardiomyocytes with resulting cell division and repopulation of infarct zone.

 Understanding the mechanistic basis for the silencing of cyclin A2 in mammalian hearts

The endogenous cyclin A2 gene is silenced in mammalian hearts shortly after birth.  We are studying epigenetic modifications of DNA and histones of the cyclin A2 promoter to gain a better understanding of why this occurs so that we can identify molecular targets for novel therapies.

Fetal-Maternal Stem Cell Transfer

As PPCM has the highest rate of spontaneous recovery of all forms of cardiomyopathy AND previous studies have established the persistence of fetal cells in the maternal circulation, the current experiments are testing:

  1. Cells originating from fetus may home to the mother’s injured heart.
  2. This may be a potential mechanism for repair in PPCM.
  3. If so, perhaps we can utilize the cell type(s) involved for repair in other forms of cardiomyopathy.

Recent Grants:

Grant: HL88255-01, NIH-NHLBI
Dates: 04/15/07 – 04/14/12
Annual Direct Costs: $250,000.00
Title: The Mechanistic Basis of Cyclin A2 Mediated Cardiac Repair
PI: Hina W. Chaudhry, MD

Grant: Sponsored Research Agreement from Broadview Ventures
Dates: 9/15/09-9/14/11
Annual Direct Costs: $439,806.00
Title:  Cardiac Regenerative Therapy with Cyclin A2
PI: Hina W. Chaudhry, MD